Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Radioactivity03:23

Types of Radioactivity

The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
Nuclear Power02:36

Nuclear Power

Controlled nuclear fission reactions are used to generate electricity. Any nuclear reactor that produces power via the fission of uranium or plutonium by bombardment with neutrons has six components: nuclear fuel consisting of fissionable material, a nuclear moderator, a neutron source, control rods, reactor coolant, and a shield and containment system.
Nuclear Fuels
Nuclear fuel consists of a fissile isotope, such as uranium-235, which must be present in sufficient quantity to provide a...
Nuclear Transmutation03:20

Nuclear Transmutation

Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed protons being...
Introduction to Nuclear Reprogramming01:14

Introduction to Nuclear Reprogramming

Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
Isotopes and Radioisotopes01:28

Isotopes and Radioisotopes

In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing more...
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The long history of the International Research Group in Immuno-Scintigraphy and Therapy (IRIST).

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2015
Same author

Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2015
Same author

A comparison of targetting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.

European journal of nuclear medicine·2014
Same author

Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of Tc-Hynic-rh-Annexin V Imaging.

Clinical medicine. Oncology·2011
Same author

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

Human antibodies·2011
Same author

[Added value of prone position technique for PET-TAC in breast cancer patients].

Revista espanola de medicina nuclear·2010
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Radionuclide therapy.

J F Chatal1, C A Hoefnagel

  • 1Department of Nuclear Medicine, René Gauducheau Cancer Centre, Nantes, France. jfchatal@nantes.inserm.fr

Lancet (London, England)
|September 18, 1999
PubMed
Summary
This summary is machine-generated.

Nuclear medicine therapy offers a targeted radiation approach for benign and cancerous conditions. This treatment is effective, with manageable side effects and favorable long-term outcomes compared to traditional therapies.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 6, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Nuclear medicine
  • Radiotherapy
  • Oncology

Background:

  • Nuclear medicine therapy utilizes unsealed radioactive sources for targeted radiation delivery.
  • It serves as an alternative to surgery or medical treatments for benign conditions like thyrotoxicosis and arthritis.
  • In cancer care, it combines targeted selectivity with systemic effects, similar to chemotherapy.

Purpose of the Study:

  • To review the applications and outcomes of nuclear medicine therapy.
  • To compare its efficacy and toxicity with conventional treatments.
  • To highlight its role in curative strategies, disease control, and palliation.

Main Methods:

  • Review of nuclear medicine therapy principles and applications.
  • Analysis of treatment outcomes for benign and malignant diseases.
  • Comparison of toxicity profiles and long-term consequences with chemotherapy and radiotherapy.

Main Results:

  • Radionuclide therapy is effective for benign disorders and cancer treatment.
  • Toxicity is primarily limited to hematopoietic tissue with few observed side-effects.
  • Long-term consequences, including secondary cancers, compare favorably with chemotherapy and radiotherapy.

Conclusions:

  • Nuclear medicine therapy is a valuable treatment modality with a favorable risk-benefit profile.
  • It offers a systemic yet targeted approach for various conditions.
  • Its long-term safety and efficacy make it a competitive option against traditional treatments.